Unshrunk: A Story of Psychiatric Treatment Resistance is more than a memoir of Laura Delano’s journey through pain, survival, and recovery. It is a fearless, forensic examination of a psychiatric system that too often harms those it is meant to help.
Former service members around the country already feel the repercussions, which include cuts to transportation programs for disabled veterans, reduced telephone support for caregivers, and the postponement or cancellation of suicide prevention trainings.
Other veterans report the cancellation of therapy groups and longer wait times for appointments as well as disruptions to medical studies, including a clinical trial on a new medication with the potential to treat cancers of the mouth and throat. Some facilities eliminated staff members especially trained or certified to perform certain roles, delaying the requisition and delivery of medical supplies.
As always happens amid Musk’s ham-handed raids, the cuts at the VA commenced without the slightest foresight or sense. Among many other examples, officials summarily canceled hundreds of contracts with outside providers, only to immediately scale back the reckless decision after realizing they needed the help performing essential work like physician recruitment and burial services.
Kaldahl, who receives hearing aids, eye care, and other services from the VA, has to travel to larger cities, such as Superior, Wisconsin, or Minneapolis, to receive care unavailable at a clinic near his home.
In 2015, six psychiatrists from the Department of Psychiatry, University of Oxford, the UK, published the study, “Depression and Violence: A Swedish Population Study” in Lancet Psychiatry.
Late last year, the U.S. Food and Drug Administration (FDA) quietly introduced a regulation that may be one of the most important shifts in how non-profit and for-profit U.S. institutions, both at home and abroad, conduct future medical and public health research. It represents an erosion of personal medical choice and threatens to undermine the public’s trust in scientific investigations in biomedicine.
A group of 400 Israeli survivors of the October 7 Hamas attack, including civilians, released hostages, and soldiers, could be offered MDMA-assisted psychotherapy in a potentially trailblazing study to commence later this year.
…
“Our goal is to create a therapy model that can serve universally, with the intention and prayer to help people,” said Dr. Keren Tzarfaty, CEO and co-founder of MAPS Israel, which is already running trials evaluating MDMA-assisted therapy for the treatment of post-traumatic stress disorder, depression, and eating disorders. “We hope it will demonstrate high levels of safety and effectiveness and enable us to offer the program in other places over the region and the world, not only to treat PTSD, but to help people open their hearts and expand their minds.”
…
Dr. Rick Doblin, founding president of the U.S.-based MAPS and a longtime advocate for using psychedelic therapy in the Israeli–Palestinian conflict, said that the study would serve as a seminal piece of research into whether psychedelic-assisted therapy can help large groups of traumatized people.
“. . . if the major media picks up on this story, they will have the chance to report on what arguably is the worst—and most harmful—scandal in American medical history”
Historically, there have always been some patients who report that any treatment for depression—including bloodletting—has worked for them, but science demands that for a treatment to be deemed truly effective, it must work better than a placebo or the passage of time without any treatment. This is especially important for antidepressant drugs—including Prozac, Zoloft, and other selective serotonin reuptake inhibitors (SSRIs), as well as Effexor, Cymbalta, and other serotonin and norepinephrine reuptake inhibitors (SNRIs)—because all of these drugs have uncontroversial troubling side effects.
Yet one glaring problem remains. Despite promising clinical results, no one knows exactly how psychedelic drugs work in the brain. Examining their actions on brain cells isn’t just an academic curiosity. It could give rise to variants that maintain antidepressant properties without the high. And because hallucinogens substantially alter our perception [management?!] of the world, they could be powerful toolsfor investigating the neurobiology behind consciousness.
…
This year, scientists found another common theme—psychedelics seem to “reset” the brain to a more youthful state, at least in mice. Like humans, mice have an adolescent critical period, during which their brains are highly malleable and can easily rewire neural circuits, but the window closes after adulthood.
…
An earlier study showed that MDMA reopens the critical window in adult mice, so that they change their “personality.” Mice raised alone are often introverted and prefer to keep to themselves in adulthood. A dose of MDMA increased their willingness to snuggle with other mice—essentially, they learned to associate socializing with happiness, concluded the study.
It’s not that surprising. MDMA is well-known to promote empathy and bonding. The new study, by the same team, extended their early results to four psychedelics that don’t trigger fuzzy feelings—LSD, ketamine, psilocybin, and ibogaine. Similar to MDMA, adult mice raised alone changed their usual preference for solitude when treated with any of the drugs. Because habits are hard to change in adulthood—for mice and men—the drugs may have reopened the critical period, allowing the brain to more easily rewire neural connections based on new experiences.
…
These are just early results. But psychedelic research is gaining a new ally—artificial intelligence. Algorithms that predict protein structure, combined with rational drug design, could generate psychedelics that retain their psychiatric benefits without the high.
A psychedelics-focused drug development company is officially asking the Food and Drug Administration (FDA) to review an application to approve MDMA as a prescription medication for the treatment of post-traumatic stress disorder (PTSD).
The MAPS Public Benefit Corporation (MAPS PBC) announced on Tuesday that it submitted the new drug application (NDA) to FDA, requesting an expedited review given that the agency previously designated the psychedelic as a breakthrough therapy.
Ms. Cat’s Chronicles 
You must be logged in to post a comment.